Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,029 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.
Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, García-Echeverría C, Weissleder R, Mahmood U, Cantley LC, Wong KK. Engelman JA, et al. Among authors: weissleder r. Nat Med. 2008 Dec;14(12):1351-6. doi: 10.1038/nm.1890. Epub 2008 Nov 30. Nat Med. 2008. PMID: 19029981 Free PMC article.
Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin.
Girnun GD, Chen L, Silvaggi J, Drapkin R, Chirieac LR, Padera RF, Upadhyay R, Vafai SB, Weissleder R, Mahmood U, Naseri E, Buckley S, Li D, Force J, McNamara K, Demetri G, Spiegelman BM, Wong KK. Girnun GD, et al. Among authors: weissleder r. Clin Cancer Res. 2008 Oct 15;14(20):6478-86. doi: 10.1158/1078-0432.CCR-08-1128. Clin Cancer Res. 2008. PMID: 18927287 Free PMC article.
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.
Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R, Chirieac LR, Padera R, Bronson RT, Kim W, Jänne PA, Shapiro GI, Tenen D, Johnson BE, Weissleder R, Sharpless NE, Wong KK. Ji H, et al. Among authors: weissleder r. Cancer Cell. 2006 Jun;9(6):485-95. doi: 10.1016/j.ccr.2006.04.022. Epub 2006 May 25. Cancer Cell. 2006. PMID: 16730237 Free article.
Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer.
Alagesan B, Contino G, Guimaraes AR, Corcoran RB, Deshpande V, Wojtkiewicz GR, Hezel AF, Wong KK, Loda M, Weissleder R, Benes CH, Engelman J, Bardeesy N. Alagesan B, et al. Among authors: weissleder r. Clin Cancer Res. 2015 Jan 15;21(2):396-404. doi: 10.1158/1078-0432.CCR-14-1591. Epub 2014 Oct 27. Clin Cancer Res. 2015. PMID: 25348516 Free PMC article.
The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling.
Taniguchi CM, Winnay J, Kondo T, Bronson RT, Guimaraes AR, Alemán JO, Luo J, Stephanopoulos G, Weissleder R, Cantley LC, Kahn CR. Taniguchi CM, et al. Among authors: weissleder r. Cancer Res. 2010 Jul 1;70(13):5305-15. doi: 10.1158/0008-5472.CAN-09-3399. Epub 2010 Jun 8. Cancer Res. 2010. PMID: 20530665 Free PMC article.
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism.
Ying H, Kimmelman AC, Lyssiotis CA, Hua S, Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, Coloff JL, Yan H, Wang W, Chen S, Viale A, Zheng H, Paik JH, Lim C, Guimaraes AR, Martin ES, Chang J, Hezel AF, Perry SR, Hu J, Gan B, Xiao Y, Asara JM, Weissleder R, Wang YA, Chin L, Cantley LC, DePinho RA. Ying H, et al. Among authors: weissleder r. Cell. 2012 Apr 27;149(3):656-70. doi: 10.1016/j.cell.2012.01.058. Cell. 2012. PMID: 22541435 Free PMC article.
Some tools for molecular imaging.
Mahmood U, Weissleder R. Mahmood U, et al. Among authors: weissleder r. Acad Radiol. 2002 Jun;9(6):629-31. doi: 10.1016/s1076-6332(03)80306-9. Acad Radiol. 2002. PMID: 12061735 No abstract available.
1,029 results